Björklund Pharma develops nutraceutical and biotech product candidates with an emphasis on formulation quality, scientific rationale, and responsible communication. The pipeline is built around targeted concepts selected for ingredient quality and alignment with European regulatory expectations. At this stage, the portfolio consists of products under development, and no medical outcomes are implied. In parallel with nutraceutical development, the biotech pipeline explores advanced bioactive candidates relevant to regeneration and repair biology. Across all areas, the focus is on building a coherent pipeline of high-quality products, supported by clear composition standards and EU-appropriate communication.